Health Catalyst, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated February 12, 2026, reports significant leadership and Board of Directors transitions at Health Catalyst, Inc. The filing details the appointment of a new Chief Executive Officer (CEO), the retirement of the former CEO, and the resignation of multiple directors, resulting in a restructuring of the Board's composition and committee leadership.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes and executive compensation arrangements.
Material Changes and Executive Compensation
- CEO Appointment: Ben Albert was appointed CEO and a Class III Director, effective February 12, 2026, succeeding Dan Burton. Mr. Albert previously served as President and COO.
- CEO Compensation: Mr. Albert's new compensation package includes a $600,000 base salary, an annual bonus target of 100% of base salary, a grant of 465,000 RSUs, and a grant of 465,000 performance-based RSUs (PRSUs). Vesting schedules for prior grants were also amended.
- Former CEO Transition: Dan Burton accelerated his retirement as CEO to February 12, 2026, and resigned from the Board effective February 17, 2026. He will transition to a strategic advisor role.
- Director Resignations:
- Dawn Smith and Duncan Gallagher resigned from the Board effective February 17, 2026.
- John A. Kane resigned as Board Chair effective February 12, 2026, and from the Board effective April 1, 2026.
- Director Compensation Adjustments: Resigning directors received accelerated vesting of RSUs (36,231 units each for Smith, Gallagher, and Kane) and/or cash/RSU retainers for the quarter ended March 31, 2026.
- Board Size Reduction: The Board size is being reduced from nine to five directors over the coming months due to these resignations and the non-reelection of another director.
Outlook, Risks, and Contingencies
The filing includes standard forward-looking statements regarding the execution of transition agreements and the vesting of equity awards. The Company notes that actual results may differ from expectations due to various risks and uncertainties. No specific financial risks or contingencies related to operations were disclosed in this filing.
Investor Verification Checklist
- Verify the full text of the Offer Letter (Exhibit 10.1) for detailed vesting metrics on the 465,000 PRSUs granted to Ben Albert.
- Confirm the timeline for the reduction of the Board size to five directors and the election of new Class I directors at the 2026 annual meeting.
- Review the transition agreement to be entered into with Dan Burton to understand the scope and duration of his role as strategic advisor.
- Monitor future filings for the impact of these leadership changes on the Company's strategic direction and operational performance.